Table 1.
Treatment assignment | 1Infusion baselines (±SEM) | |||
---|---|---|---|---|
Dose (mg/kg) | Males | n | Females | n |
Zol 0 | 23.87 (±1.28) | 14 | 23.57 (±1.62) | 14 |
Zol 3.0 | 23.48 (±0.95) | 14 | 26.19 (±2.38) | 14 |
Zol 5.6 | 22.76 (±0.99) | 14 | 25.10 (±2.15) | 14 |
Zol 10 | 23.02 (±1.52) | 14 | 23.71 (±2.03) | 14 |
SB 3.2 | 27.56 (±1.67) | 13 | 30.33 (±3.18) | 10 |
SB 5.6 | 28.57 (±2.40) | 14 | 27.02 (±1.33) | 10 |
SB 10 | 28.10 (±2.11) | 13 | 29.70 (±3.28) | 10 |
SB 3.2 + Zol 5.6 | 26.58 (±2.44) | 13 | 29.85 (±1.51) | 10 |
SB 5.6 + Zol 5.6 | 27.73 (±2.63) | 13 | 28.05 (±1.86) | 10 |
SB 10 + Zol 5.6 | 27.57 (±1.92) | 14 | 27.82 (±2.12) | 10 |
BRL 0.3 | 26.90 (±1.73) | 10 | 22.50 (±1.58) | 8 |
BRL 1.0 | 28.43 (±2.25) | 14 | 27.42 (±1.54) | 11 |
BRL 3.0 | 27.85 (±1.96) | 14 | 27.47 (±2.95) | 12 |
BRL 0.3 + Zol 5.6 | 26.72 (±1.64) | 10 | 22.10 (±1.68) | 8 |
BRL 1.0 + Zol 5.6 | 27.92 (±1.92) | 12 | 27.49 (±2.96) | 13 |
BRL 3.0 + Zol 5.6 | 28.07 (±2.33) | 12 | 26.44 (±2.20) | 13 |
1Average of the three consecutive baseline sessions prior to each treatment test; SB = SB224289; BRL = BRL15572; Zol = Zolmitriptan.